APPENDIX II-CD:
Doyle, “Deadly
This appendix is copied from:
http://www.rense.com/general3/profit.htm
Rense.com
Deadly West Nile Virus
For Profit - Vaccine
Award Announced
By Patricia Doyle <labgal_5@yahoo.com>
8-3-00
When I first began writing
articles, and doing radio show interviews about the New York West Nile
outbreak I mentioned the OraVax ompany
in
Plans for this vaccine were
in the works prior to 1996. It was in 1996 when OraVax
Co. was granted permission to license genetically altered Japanese
Encephalitis which had been exclusively created and patented by the
It is no surprise that OraVax would get the
I had further discussed an
alliance between Dr. Jerry Hauer, former head of
the Office of Emergency Management for
OraVax had said on its own website that Phase 2 trials
were scheduled to commence this Fall 2000. We now have breaking news that OraVax was granted 3 million dollars to develop a
There have been those, like
myself, who knew the vaccine was in the making and who suspected that the
I believe that is why the
virus was "allegedly" released in
I sincerely hope that our
elected officials will make a sincere investigation into the origin of the
non-endemic
Thank you,
Patricia
_____
The Financial Times -
Peptide Therapeutics, the
For the past 10 months I have been writing about a bio-chemical corporation, Oravax, in relation to the so-called WNV (West Nile Virus) epidemic in NYC. The V.P of Oravax, Dr. Thomas Monath has been working behind the scenes with Mayor Giuliani, former OEM chief Jerry Hauer, Dr. Cohen and the CDC since the very beginning of this issue.
From: Newsday
9/25/99-Deadly Discovery "Virologist Thomas Monath,
one of the country's leading authorities on mosquito-carried viruses, called
the discovery ``a bombshell,'' and added: `` This is the biggest arbovirus story of the last 50 years. Wow!'' Monath, who works for OraVax, a
biotechnology company in
As predicted, Oravax has now been given a grant from the N.I.H.
(National Institute of Health) to create a WNV vaccine. The theory I and a
number of other activists have been suggesting is that the entire WNV panic
has been created specifically in order to justify the mass distribution of
this very vaccine throughout the entire
Oravax was granted a license by the U.S. Army bio-warfare
lab in
According to the press
release and articles below the vaccine is a live, attenuated vaccine (it
contains live WN virus) and involves "the construction of a chimeric virus in which the envelope genes of yellow
fever vaccine are replaced with the corresponding genes of the target
Since the vaccine is made from a genetically-altered strain there is no way to know exactly what other theoretically beneficial or harmful genes may have been added. Scientists in the field of GE foods (genetically-altered foods) have already found evidence that genes in the pollen of these foods can become incorporated into the DNA of insects that pollinate the GE plants. In other words it is possible to incorporate these genes into your own DNA simply by eating the food, or in this instance, orally taking a vaccine. _____
From: biotech_activists@iatp.org "Tappeser" <tappeser@oeko.de Organization: Oeko-Institute e.V.
Subject: new stories from
"The German Television
ZDF reported on Sunday May 21 that a German researcher found a gene transfer
from genetically engineered rapeseed to bacteria and fungi in the gut of
honey bees. Prof. Hans-Hinrich Kaatz
from the Institut fºr Bienenkunde (Institute for bee research) at the
Mayor Giuliani and his advisors have been massively spraying NYC with a variety of toxic pesticides since last Fall, despite knowing that experts in the field of mosquito control have determined that such spraying actually increases the number of mosquitoes, makes succeeding generations pesticide resistant and increases the incidence of mosquitoes infected with transmissible viruses like WNV by as much as 15 times. [see: Are Mosquito Spray Pesticides Worsening the Encephalitis Problem? http://www.chem-tox.com/brevard/index.htm SOURCE: Journal of the American Mosquito Control Assoc, Dec;13(4):315-25, 1997 Howard JJ, Oliver New York State Department of Health, SUNY-College ESF, Syracuse 13210, USA. Also see my articles on this http://baltech.org/lederman/spray/]
Considering the mild nature of WNV their actions appear to be intended to increase WNV rather than to decrease it. Dr. Cohen implied as much two days ago. _____
Spray It Ain't So! Round 2 On S.I.
"Cohen said...Part of the reason for the new skeeter woes is that between 10 and 20 percent of the bugs won't be killed by the pesticide [the ones that are resistant to the chemicals] - and those that live will reproduce, Cohen said....Cohen said the traps were nearly empty in the first two days after the initial Staten Island spraying last month, but now they're filling up again."This is not unexpected," he insisted."
That Dr. Cohen acknowledges he knows that the spraying would lead to new generations of pesticide resistant mosquitoes supports the idea that the spraying is actually intended to help create a demand for the vaccine, which the NYC officials unquestionably knew was already in development and testing. What the real purpose of the vaccine is one can only guess at this point. _____
Germ Defense Plan In Peril As Its Flaws Are Revealed
New York Times
If you carefully read the very long article this is excerpted from you will see detailed evidence of how Dr. Monath, former Giuliani OEM chief Jerry Hauer, the president of Rockefeller University (where they have experimented with WNV for decades) and Dr. J. Craig Venter, president of The Institute for Genomic Research (the co-researchers and co-owners of the Human Genome Project) have been pressuring President Clinton to spend billions on a nationwide vaccine program against germ warfare.
EXCERPT
"In April, the
president...and his top officials met at the White House on April 10 with
seven private scientists in the
From: http://info.med.yale.edu/EIINet/MonathSeminar.html
(Note how the VP of Oravax, manufacturer of the encephalitis vaccine who is advising Giuliani on this crisis, was both a researcher at Ft. Dietrick Bio-Warfare lab and a CDC scientist.)
"Thomas Monath is one of the world's leading arbovirologists.
He is currently Vice- President of Research and Medical Affairs at OraVax, Inc. in
From Patricia Doyle abgal_5@yahoo.com
Here is the way the article appears on the Peptide Theraputic website:
Peptide awarded grant by
NIH to develop
Cambridge, UK - 1 August 2000 - Peptide Therapeutics Group ("Peptide") announces that it s US subsidiary, OraVax Inc. has been awarded a Fast-Track Small Business Innovative Research (SBIR) grant by the US National Institutes of Health ("NIH") to develop an important new vaccine to prevent West Nile virus disease ("West Nile").
Fears are growing that
another outbreak could occur this year. Infected birds and mosquitoes have
been detected over a wide area from
The grant has been awarded
through Peptide's
The
Dr Thomas Monath, Vice President Research & Medical Affairs of
Peptide, said: "The advantages of ChimeriVax™
vaccines include their high safety profile, ability to induce protection
within a few days after a single dose, and long-lasting immunity without the
need for booster doses. A ChimeriVax™
Dr John Brown, Chief
Executive of Peptide, said: "We are delighted to have been selected by
the
Enquiries: Peptide Therapeutics Group plc
Dr John Brown, Chief Executive Tel: + 44 1223 275300
Dr Thomas Monath, Vice President Research & Medical Affairs Tel: +1 617 494 1339
Web site: www.peptide.co.uk Financial Dynamics David Yates/Sophie Pender-Cudlip Tel: +44 207 831 3113
Notes to Editors
1. Peptide
Peptide is a
biopharmaceutical company developing vaccines to prevent and treat infectious
diseases. It is based in
2. ChimeriVax™
The ChimeriVax™
technology platform is a method for development of new vaccines against
viruses in the family Flaviviridae. The technology
utilizes a molecular clone of yellow fever 17D, one of the safest and most
effective vaccines ever developed, as the foundation for construction of new
live, attenuated vaccines against related Flaviviruses.
To generate a new vaccine, the genes for the viral envelope of yellow fever
17D virus are replaced with the corresponding genes of the target virus, for
example West Nile, creating a yellow fever-West Nile hybrid or ëchimeraí. The new virus contains
The ChimeriVax™ technology is being developed in several product programmes including vaccines against dengue fever, Japanese encephalitis, tick-borne encephalitis and hepatitis C. Peptideís most advanced programme using this technology is to develop a vaccine against Japanese encephalitis, the leading cause of viral infection of the central nervous system in Asia. Phase I trials are scheduled to commence shortly.
3.
There is no vaccine, cure
or specific therapy for
Area Labs Have Long Studied Virus Yale, Rockefeller Began Tests In '50s
Newday 9-29-99
" Epidemiologists suspect that the West Nile virus has for the first time been isolated in humans or animals in the Western Hemisphere, but the virus has for decades made its home in several U.S. research laboratories, including Rockefeller University in Manhattan and Yale University in New Haven, Conn. In fact, investigators there were the first to grow and study the West Nile virus in the United States. The work began in the 1950s when unidentified viral samples from around the world arrived at Rockefeller on a steady basis."
Mosquito From Asia Could Carry West Nile
Newsday 5-9-00
(AP) - In Army tests at Fort Detrick in Frederick, Md., japonicus was found to be the "most competent vector" [transmittter] for West Nile virus in a laboratory setting, when compared with other mosquitoes."
From: http://www.bioinfo.com/jev.html [from Federal Register: March 22, 1996 (Volume 61, Number 57, Page 11812] DEPARTMENT OF DEFENSE Notice of Intent To Grant an Exclusive License of a U.S. Government-Owned Patent Agency: U.S. Army Medical Research and Materiel Command, DOD [Department of Defense]. Action: Notice.
Summary
In accordance with 37 CFR 404.7 (a)(I)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license of U.S. Patent Application Serial Number 08/348,882, filed November 28, 1994 and entitled ``Infectious DNA Clones of Japanese Encephalitis Virus and Attenuated Strains Japanese Encephalitis Virus Made from the Clones'', to OraVax, Inc., 230 Albany Street, Cambridge, Massachusetts 02139. [Requests to the Army for further information should be directed to the public affairs officer, Mr. Chuck Dasey (301) 619-2736]
Robert Lederman, President of A.R.T.I.S.T. (Artists,Äô Response To Illegal State Tactics) ARTISTpres@aol.com (718) 743-3722 http://www.levymultimedia.com/lederman/index.htm For an article on the Manhattan Institute go to http://www.konformist.com/2000/rudyg.htm
If you would like to help oppose the spraying, please write to the No Spray Coalition, PO Box 334, Peck Slip Station, NYC 10272-0334, or call the No Spray hotline at (718) 670-7110. Any funds you can send to help continue the lawsuit and this work are greatly appreciated. http://www.nospray.org/
For Lederman articles with more on this information see http://baltech.org/spray/ http://Baltech.org/lederman/spray/ _____
Bugged by Spraying
Newsday 10-10-99
The loudest protests heard during the city's recent campaign of insecticide spraying came from the city's tiny Green Party and the artist-agitator Robert Lederman...Yesterday, the head of the mayor's Office of Emergency Management, which took the lead in the assault on the city's mosquito populace, dismissed such concerns as "irresponsible environmental hysteria and stupidity." "If they took a deep breath [of Malathion?] and looked at what we did and what pains we went through to ensure that we did it right and recognize that human life is at stake, they'd get the perspective," said OEM Director Jerry Hauer.,Äù _____
From: ARTISTpres@aol.com Date: Subject: Fwd: Award granted for W. Nile vaccine
The virus killed seven
people and sickened more than 60 in the
The company, OraVax Inc., plans to develop the
"This is a live viral
vaccine like one for measles or mumps or polio," said Thomas Monath, OraVax,Äôs
vice president of research and medical affairs. ,ÄúIt will cause a very mild infection with no
symptoms and leave the person immunized against
OraVax, a Cambridge, Mass.-based subsidiary of Britain,Äôs Peptide The virus killed seven people and
sickened more than 60 in the New York City area last year, its first
appearance in the Western Hemisphere. Therapeutics Group,
has been working on a
No
human deaths have been reported this year, but mosquitoes carrying the virus
have been found in parts of
|